Network mirroring for drug repositioning
暂无分享,去创建一个
[1] Hyunjung Shin,et al. CLASH: Complementary Linkage with Anchoring and Scoring for Heterogeneous biomolecular and clinical data , 2016, BMC Medical Informatics and Decision Making.
[2] Alan F. Scott,et al. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..
[3] P. Jaccard. Distribution de la flore alpine dans le bassin des Dranses et dans quelques régions voisines , 1901 .
[4] A. V. Grimstone. Molecular biology of the cell (3rd edn) , 1995 .
[5] K. Coyne,et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.
[6] Evgueni A. Haroutunian,et al. Information Theory and Statistics , 2011, International Encyclopedia of Statistical Science.
[7] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[8] Robert B. Russell,et al. SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..
[9] Joel Dudley,et al. Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..
[10] X. Chen,et al. TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..
[11] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[12] I. Goldstein,et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.
[13] Hyunjung Shin,et al. Research and applications: Breast cancer survivability prediction using labeled, unlabeled, and pseudo-labeled patient data , 2013, J. Am. Medical Informatics Assoc..
[14] Tom F. Lue,et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.
[15] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[16] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[17] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[18] Pankaj Agarwal,et al. A Pathway-Based View of Human Diseases and Disease Relationships , 2009, PloS one.
[19] Xia Li,et al. The expanded human disease network combining protein–protein interaction information , 2011, European Journal of Human Genetics.
[20] I. Milsom,et al. The prevalence of urinary incontinence , 2000, Acta obstetricia et gynecologica Scandinavica.
[21] R. Basha,et al. Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies , 2015, Journal of Neurochemistry.
[22] C. Mathers,et al. Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.
[23] E. Finger. New Potential Therapeutic Approaches in Frontotemporal Dementia: Oxytocin, Vasopressin, and Social Cognition , 2011, Journal of Molecular Neuroscience.
[24] A. Chiang,et al. Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.
[25] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[26] Alexander Zien,et al. Semi-Supervised Learning , 2006 .
[27] I. Khanna,et al. Drug discovery in pharmaceutical industry: productivity challenges and trends. , 2012, Drug discovery today.
[28] N. Campbell. Genetic association database , 2004, Nature Reviews Genetics.
[29] Xin Chen,et al. DCDB 2.0: a major update of the drug combination database , 2014, Database J. Biol. Databases Curation.
[30] Tatiana A. Tatusova,et al. Entrez Gene: gene-centered information at NCBI , 2004, Nucleic Acids Res..
[31] Philip E. Bourne,et al. Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..
[32] C E Lipscomb,et al. Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.
[33] A. Wimo,et al. The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.
[34] S. Rees,et al. Principles of early drug discovery , 2011, British journal of pharmacology.
[35] Darcy A. Davis,et al. Exploring and Exploiting Disease Interactions from Multi-Relational Gene and Phenotype Networks , 2011, PloS one.
[36] Joel Dudley,et al. Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..
[37] Yanli Wang,et al. PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..
[38] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[39] Weida Tong,et al. In silico drug repositioning: what we need to know. , 2013, Drug discovery today.
[40] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[41] Huaiyu Zhu. On Information and Sufficiency , 1997 .
[42] Ehud Weinstein,et al. Sequential algorithms for parameter estimation based on the Kullback-Leibler information measure , 1990, IEEE Trans. Acoust. Speech Signal Process..
[43] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[44] Thomas C. Wiegers,et al. The Comparative Toxicogenomics Database: update 2013 , 2012, Nucleic Acids Res..
[45] Albert-László Barabási,et al. A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..
[46] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[47] David S. Wishart,et al. T3DB: a comprehensively annotated database of common toxins and their targets , 2009, Nucleic Acids Res..
[48] M. F. Beal,et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.
[49] P. Sanseau,et al. Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.